Affiliation:
1. 3rd Medical Center of Chinese PLA General Hospital
2. Chinese PLA General Hospital
Abstract
Abstract
Background
Cisplatin (CDDP)-based chemotherapy is a standard first-line treatment for metastatic bladder cancer (BCa) patients, and chemoresistance remains a major challenge in clinical practice. Circular RNAs (circRNAs) have emerged as essential regulators in carcinogenesis and cancer progression. However, the role of circRNAs in mediating CDDP chemosensitivity has yet to be well elucidated in BCa.
Methods
CircSTX6 (hsa_circ_0007905) was identified by mining the public circRNA datasets and verified by Sanger sequencing, agarose gel electrophoresis, RNase R treatment and qRT-PCR assays. Then, function experiments were performed to evaluate the effects of circSTX6 on BCa metastasis. Luciferase reporter assay, RNA pull-down, RNA immunoprecipitation (RIP), RNA stability assay, fluorescence in situ hybridization (FISH) and immunofluorescence (IF) were conducted to evaluate the interaction among circSTX6, miR-515-3p, PABPC1 and SUZ12. Animal experiments were performed to explore the function of circSTX6 in tumor metastasis and CDDP sensitivity.
Results
We identified that circSTX6 was significantly upregulated in clinical samples and cells of BCa. Functionally, circSTX6 promoted cell migration and invasion both in vitro and in vivo. Mechanistically, circSTX6 could act as a miR-515-3p sponge and abolish its effect on SUZ12. Moreover, circSTX6 was confirmed to increase the stability of SUZ12 mRNA by interacting with a mRNA stabilizer PABPC1 and subsequently promote the expression of SUZ12. Importantly, silencing of circSTX6 improved the chemosensitivity of cisplatin-resistant bladder cancer cells to cisplatin. Furthermore, in vivo analysis supported that knockdown of circSTX6 attenuated the CDDP resistance in BCa tumors.
Conclusion
These studies demonstrate that circSTX6 plays a pivotal role in BCa metastasis and chemoresistance, and has potential to serve as a therapeutic target for treatment of BCa.
Publisher
Research Square Platform LLC
Reference60 articles.
1. Cancer statistics, 2022;Siegel RL;CA Cancer J Clin,2022
2. Bladder cancer;Sanli O;Nat Rev Dis Primers,2017
3. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines;Witjes JA;Eur Urol,2021
4. Treatment of muscle-invasive and advanced bladder cancer in 2020;Patel VG;CA Cancer J Clin,2020
5. Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, Choi W et al. Bladder cancer Lancet. 2016;(388):2796–810.